These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 7427961)

  • 1. Clinical pharmacology of tamoxifen in patients with breast cancer: comparison of traditional and loading dose schedules.
    Fabian C; Sternson L; Barnett M
    Cancer Treat Rep; 1980; 64(6-7):765-73. PubMed ID: 7427961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacology of tamoxifen in patients with breast cancer: correlation with clinical data.
    Fabian C; Sternson L; El-Serafi M; Cain L; Hearne E
    Cancer; 1981 Aug; 48(4):876-82. PubMed ID: 7272932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
    Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T
    Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer.
    Budd GT; Adamson PC; Gupta M; Homayoun P; Sandstrom SK; Murphy RF; McLain D; Tuason L; Peereboom D; Bukowski RM; Ganapathi R
    Clin Cancer Res; 1998 Mar; 4(3):635-42. PubMed ID: 9533531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum and urine levels of tamoxifen and its metabolites in patients with advanced breast cancer after a loading dose and at steady-state levels.
    de Vos D; Slee PH; Briggs RJ; Stevenson D
    Cancer Chemother Pharmacol; 1998; 42(6):512-4. PubMed ID: 9788580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
    Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
    Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.
    Samuels BL; Hollis DR; Rosner GL; Trump DL; Shapiro CL; Vogelzang NJ; Schilsky RL
    Clin Cancer Res; 1997 Nov; 3(11):1977-84. PubMed ID: 9815587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
    Greenblatt MS; Mangalik A; Ferguson J; Elias L
    Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
    De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR
    Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trial of tamoxifen at a dose of 40 mg daily after disease progression during tamoxifen therapy at a dose of 20 mg daily.
    Stewart JF; Minton MJ; Rubens RD
    Cancer Treat Rep; 1982 Jun; 66(6):1445-6. PubMed ID: 7044536
    [No Abstract]   [Full Text] [Related]  

  • 12. [Phase I study of TAT-59 (a new antiestrogen) in breast cancer. TAT-59 Study Group].
    Nomura Y; Abe O; Enomoto K; Fujiwara K; Tominaga T; Hayashi K; Uchino J; Takahashi M; Hayasaka A; Asaishi K; Okazaki M; Abe R; Kimishima I; Kajiwara T; Haga S; Shimizu T; Miyazaki I; Noguchi M; Yoshida M; Miura S; Taguchi T; Oota J; Sakai K; Kinoshita H; Tashiro H
    Gan To Kagaku Ryoho; 1998 Mar; 25(4):553-61. PubMed ID: 9530362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Plasma concentrations of toremifene citrate and N-desmethyltoremifene in postmenopausal patients with breast cancer--comparison of 120 mg of toremifene citrate administered once a day and divided into 3 separate doses (t.i.d.)].
    Shiba E; Watanabe T; Taguchi T; Tsukamoto F; Noguchi S
    Gan To Kagaku Ryoho; 2000 Feb; 27(2):245-9. PubMed ID: 10700895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Results of phase II clinical trial of Tamoxifen and Toremifen in two different doses in advanced breast cancer in postmenopausal women].
    Gershanovich ML; Garin AM; Baltinia D; Kurvet A; Kangas L; Ellmen Iu
    Vopr Onkol; 1997; 43(6):587-95. PubMed ID: 9479357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313).
    Linden HM; Haskell CM; Green SJ; Osborne CK; Sledge GW; Shapiro CL; Ingle JN; Lew D; Hutchins LF; Livingston RB; Martino S
    J Clin Oncol; 2007 Feb; 25(6):656-61. PubMed ID: 17308269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
    Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
    Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.
    Cataliotti L; Buzdar AU; Noguchi S; Bines J; Takatsuka Y; Petrakova K; Dube P; de Oliveira CT
    Cancer; 2006 May; 106(10):2095-103. PubMed ID: 16598749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy and safety of high dose NK 622 (toremifene citrate) in tamoxifen failed patients with breast cancer].
    Asaishi K; Tominaga T; Abe O; Izuo M; Nomura Y
    Gan To Kagaku Ryoho; 1993 Jan; 20(1):91-9. PubMed ID: 8422190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of postmenopausal breast cancer patients following discontinuation of tamoxifen therapy.
    Markovitch O; Tepper R; Fishman A; Aviram R; Cohen I
    Maturitas; 2008 Apr; 59(4):387-93. PubMed ID: 18490117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
    Kaufmann M; Rody A
    Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.